<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624268</url>
  </required_header>
  <id_info>
    <org_study_id>COMP 005</org_study_id>
    <nct_id>NCT05624268</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of a Single Administration of COMP360 in Participants With TRD</brief_title>
  <official_title>A Phase III, Multicentre, Randomised, Double Blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of a Single Administration of COMP360 in Participants With Treatment-resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>COMPASS Pathways</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>COMPASS Pathways</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with&#xD;
      treatment-resistant depression (TRD)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III, international, multi-centre, randomised, parallel group, fixed&#xD;
      single-dose, double-blind, placebo-controlled study. The study population will include&#xD;
      participants aged ≥18 years with TRD.&#xD;
&#xD;
      Overall, 378 participants will be randomised in a 2:1 ratio to receive COMP360 25 mg or&#xD;
      placebo.&#xD;
&#xD;
      The study will last up to 16 weeks including a three- to ten-week Screening Period and&#xD;
      six-week follow-up from investigational product (IP) administration.&#xD;
&#xD;
      In this study, the aim is to assess the efficacy of COMP360 25 mg versus placebo for reducing&#xD;
      symptom severity in TRD, when administered with psychological support.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2023</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COMP360 25 mg versus placebo for the change from baseline in MADRS total score</measure>
    <time_frame>Week 6</time_frame>
    <description>Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COMP360 25 mg versus placebo for the change from baseline in SDS total score</measure>
    <time_frame>Week 6</time_frame>
    <description>Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">378</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>25 mg COMP360 Psilocybin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg COMP360 Psilocybin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>COMP360 Psilocybin administered under supportive conditions</description>
    <arm_group_label>25 mg COMP360 Psilocybin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>COMP360</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥18 years at Screening&#xD;
&#xD;
          2. Major depression without psychotic features (single or recurrent episode as informed&#xD;
             by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition [DSM-5])&#xD;
&#xD;
          3. If the current major depressive episode is the participant's first lifetime episode of&#xD;
             depression, the length of the current episode must be ≥3 months and ≤2 years at&#xD;
             Screening&#xD;
&#xD;
          4. MADRS total score ≥20 at Screening and Baseline to ensure at least moderate severity&#xD;
             of depression&#xD;
&#xD;
          5. TRD, defined as failure to respond to an adequate dose and duration of two, three, or&#xD;
             four different pharmacological treatments for the current episode as determined&#xD;
             through the Massachusetts General Hospital Antidepressant Treatment Response&#xD;
             Questionnaire (MGH-ATRQ) and using the supplementary advice on additional&#xD;
             antidepressants not included in MGH-ATRQ.&#xD;
&#xD;
          6. At Screening, agreement to discontinue all prohibited medications.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        Psychiatric Exclusion Criteria:&#xD;
&#xD;
          1. Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia,&#xD;
             schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless&#xD;
             substance induced or due to a medical condition), antisocial personality disorder as&#xD;
             assessed by a structured clinical interview (MINI 7.0.2)&#xD;
&#xD;
          2. Lifetime paranoid, schizoid, schizotypal, histrionic, narcissistic personality&#xD;
             disorder, or any ongoing serious psychiatric comorbidity based on medical history and&#xD;
             clinical judgement&#xD;
&#xD;
          3. Borderline personality disorder as demonstrated by medical history or the Mini&#xD;
             International Neuropsychiatric Interview Plus (MINI plus) - borderline personality&#xD;
             disorder module&#xD;
&#xD;
          4. Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia&#xD;
             nervosa as assessed by medical history and a structured clinical interview (MINI&#xD;
             7.0.2)&#xD;
&#xD;
          5. Psychiatric inpatient within the past 12 months prior to Screening&#xD;
&#xD;
          6. Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation&#xD;
             during the current depressive episode&#xD;
&#xD;
          7. Transcranial magnetic stimulation within the past six months prior to Screening&#xD;
&#xD;
          8. Current enrolment in a psychological therapy programme that will not remain stable for&#xD;
             the duration of the study. Psychological therapies cannot have been initiated within&#xD;
             30 days prior to Screening&#xD;
&#xD;
          9. Exposure to COMP360 psilocybin therapy prior to Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Director, MD</last_name>
    <email>COMP005@compasspathways.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kadima Neuropsychiatry Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Feifel, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Feifel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uptown Research Institute, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Sonnenburg, MD</last_name>
    </contact>
    <investigator>
      <last_name>John Sonnenburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheppard Pratt Health System</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Aaronson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CBH Health, LLC</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elia Acevedo-Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharmasite Research, Inc</name>
      <address>
        <city>Pikesville</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hinda Dubin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hellerstein, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Hellerstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Medical Research Network, LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Careri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jason Careri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Health Science Center at Houston (UTHSC-H)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jair Soares, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jair Soares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedar Clinical Research</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reid Robison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedar Clinical Research</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Thielking, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedar Clinical Research - Salt Lake</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Clark Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>May 5, 2023</last_update_submitted>
  <last_update_submitted_qc>May 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psilocybin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

